Jan Hillert

Jan Hillert

Auto-generated profile, based on publicly available information

Jan Hillert

Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2007 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
FLFrida Lundmark
Frida Lundmark
KDKristina Duvefelt
Kristina Duvefelt
EIEllen Iacobaeus
Ellen Iacobaeus
IKIngrid Kockum
Ingrid Kockum
EWErik Wallström
Erik Wallström
JHJan Hillert
Jan Hillert

5 June 2015 in Acta Neurologica Scandinavica
Verified
Journal Article
Open access
PDF file
JHJ. Hillert
J. Hillert
LSL. Stawiarz
L. Stawiarz
The Swedish MS registry (SMSreg) is designed to assure quality health care for patients with multiple sclerosis (MS). It has been active since 2001 and web-based since 2004. It runs on government funding only and is used in all Swedish neurology departments. The SMSreg currently includes data on 14,500 of Sweden's estimated 17,500 prevalent patients with MS. One important function of SMSreg, to which participation is voluntary, is to serve as a tool for decision support and to provide an easy overview of the patient information needed at clinical visits. This is its core feature and explains why the majority of Swedish MS specialists contribute data. Another success factor for SMSreg is that entered data can be readily accessed, either through a query function into Excel format or through a set of predesigned tables and diagrams in which parameters can be selected. Recent development includes a portal allowing patients to view a summary of their registered data and to report a set of patient-reported outcomes. SMSreg data have been used in close to 100 published scientific reports. Current projects include an incidence cohort (EIMS), post-marketing cohorts of patients on novel disease-modifying drugs (IMSE), and a prevalence cohort (GEMS). As these studies combine physical sampling and questionnaire data with clinical documentation and possible linkage to other public registries, together they provide an excellent platform for integrated MS research.

22 October 2013 in European Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
AHAnna Karin Hedström
Anna Karin Hedström
JHJan Hillert
Jan Hillert
TOTomas Olsson
Tomas Olsson
LALars Alfredsson
Lars Alfredsson
Smoking is one of the most established risk factors for multiple sclerosis (MS). The aim of this study was to investigate how age at smoking debut, duration, intensity and cumulative dose of smoking, and smoking cessation influence the association between smoking and MS risk. In two Swedish population-based case–control studies (7,883 cases, 9,264 controls), subjects with different smoking habits were compared regarding MS risk, by calculating odds ratios with 95 % confidence intervals. We observed a clear dose response association between cumulative dose of smoking and MS risk (p value for trend <10−35). Both duration and intensity of smoking contributed independently to the increased risk of MS. However, the detrimental effect of smoking abates a decade after smoking cessation regardless of the cumulative dose of smoking. Age at smoking debut did not affect the association between smoking and MS. Smoking increases the risk of MS in a dose response manner. However, in contrary to several other risk factors for MS that seem to affect the risk only if the exposure takes place during a specific period in life, smoking affects MS risk regardless of age at exposure, and the detrimental effect slowly abates after smoking cessation.

3 February 2017 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
AMAli Manouchehrinia
Ali Manouchehrinia
HWHelga Westerlind
Helga Westerlind
EKElaine Kingwell
Elaine Kingwell
FZFeng Zhu
Feng Zhu
RCRobert Carruthers
Robert Carruthers
JHJan Hillert
Jan Hillert
The Multiple Sclerosis Severity Score (MSSS) is obtained by normalising the Expanded Disability Status Scale (EDSS) score for disease duration and has been a valuable tool in cross-sectional studies. To assess whether use of age rather than the inherently ambiguous disease duration was a feasible approach. We pooled disability data from three population-based cohorts and developed an Age Related Multiple Sclerosis Severity (ARMSS) score by ranking EDSS scores based on the patient’s age at the time of assessment. We established the power to detect a difference between groups afforded by the ARMSS score and assessed its relative consistency over time. The study population included 26058 patients from Sweden (n = 11846), Canada (n = 6179) and the United Kingdom (n = 8033). There was a moderate correlation between EDSS and disease duration (r = 0.46, 95% confidence interval (CI): 0.45–0.47) and between EDSS and age (r = 0.44, 95% CI: 0.43–0.45). The ARMSS scores showed comparable power to detect disability differences between groups to the updated and original MSSS. Since age is typically unbiased and readily obtained, and the ARMSS and MSSS were comparable, the ARMSS may provide a more versatile tool and could minimise study biases and loss of statistical power caused by inaccurate or missing onset dates.

1 October 2015 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
RRRyan Ramanujam
Ryan Ramanujam
AHAnna-Karin Hedström
Anna-Karin Hedström
AMAli Manouchehrinia
Ali Manouchehrinia
LALars Alfredsson
Lars Alfredsson
TOTomas Olsson
Tomas Olsson
JHJan Hillert
Jan Hillert
Quiz Ref ID Multiple sclerosis (MS) is a complex neurological disorder, occurring in approximately 189 of 100 000 individuals in Sweden.1 A chronic inflammatory disorder of the central nervous system, it manifests in an autoimmune attack against the myelin sheathing axons. Myelin degeneration and subsequent axonal loss result in neurological symptoms such as motor and sensory disturbance, speech and vision impairment, and moderate cognitive decline. After an initial course of irregular and worsening relapses, MS usually changes gradually after approximately 20 years into secondary progressive (SP) disease.2 The timespan from onset to conversion to SPMS is a frequently used measure of disease progression.

17 October 2016 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
PDF file
AKAndrius Kavaliunas
Andrius Kavaliunas
AMAli Manouchehrinia
Ali Manouchehrinia
LSLeszek Stawiarz
Leszek Stawiarz
RRRyan Ramanujam
Ryan Ramanujam
JAJonas Agholme
Jonas Agholme
JHJan Hillert
Jan Hillert
Objectives: The aim of this study was to identify factors influencing the long-term clinical progression of multiple sclerosis (MS). A special objective was to investigate whether early treatment decisions influence outcome. Methods: We included 639 patients diagnosed with MS from 2001 to 2007. The median follow-up time was 99 months (8.25 years). Cox regression models were applied to identify factors correlating with the outcome variable defined as time from treatment start to irreversible score 4 of the Expanded Disability Status Scale (EDSS). Results: Patients initiated on treatment later had a greater risk of reaching EDSS 4 (hazard ratio of 1.074 (95% confidence interval (CI), 1.048−1.101)), increased by 7.4% for every year of delay in treatment start after MS onset. Patients who started treatment after 3 years from MS onset reached the outcome sooner with hazard ratio of 2.64 (95% CI, 1.71−4.08) compared with the patients who started treatment within 1 year from MS onset. Baseline EDSS and age at onset were found to be predictive factors of disability progression. Conclusion: Early treatment initiation was associated with a better clinical outcome. In addition, we confirmed the well-established prognostic factors of late age at onset and early disability.